Transplant Biology & Therapy

8.7.1摘要：移植生物学和治疗 移植生物学和治疗（TBT）计划是一个历史悠久的组织，代表了30多年的历史。 合作的翻译研究。由医学博士丹尼尔·韦斯多夫领导。约翰·E瓦格纳，医学博士，技术性贸易壁垒 该计划有38名成员，代表隶属于七个部门和研究所的研究人员， 学校（医学院，药学院，公共卫生学院）。截至2007年10月1日， 有61个不同的（27同行评审; 34其他）外部资助的研究赠款提供了15.3美元的总额 自2003年6月以来，他们的研究已经产生了288个 出版物中，47%为方案内出版物，18%为方案间出版物。中央 该计划的研究主题包括造血和noh-hematopoietic干细胞生物学， 造血细胞移植（HCT），免疫生物学和基于免疫的治疗以及研究 组织修复、围移植并发症、存活率/晚期效应和生活质量。程序 强调用于治疗应用的新药的转化开发和在l-ll期的测试 临床试验，未来的目标是将癌症中心启动的I期和II期研究转移到 多机构III期临床试验。该计划的科学目标是推进 对人类造血和非造血干细胞及其衍生群体认识，进展 对先天性和适应性免疫以及免疫重建的理解及其在治疗 与HCT联合，开发新的治疗方法，以消除或减少移植相关的 移植失败、急性和慢性移植物抗宿主病（GVHD）、机会性感染的风险 和复发，并改善HCT幸存者的短期和长期生活质量。自1974年成立以来， 技术性贸易壁垒计划一直是该领域的世界领导者，它促进和提高了 移植治疗通过基础和转化研究，最终应用于病人的护理。 TBT项目研究人员利用明尼苏达大学癌症中心的所有资源， 临床和基础实验室研究。

8.7.1 ABSTRACT: TRANSPLANT BIOLOGY AND THERAPY The Transplant Biology and Therapy (TBT) Program, is a long-established group representing over 30 years of collaborative translational investigation. Led by Daniel Weisdorf, M.D. and John E.. Wagner, M.D., the TBT Program has 38 members, representing investigators affiliated with seven departments and Institutes within schools (Medical School, College of Pharmacy, School of Public Health). As of October 1, 2007, members had 61 distinct (27 peer-reviewed; 34 other) externally funded research grants providing a total of $15.3 million in total support for the current budget period (: Since June 2003, their research has resulted in 288 publications, of which 47% were intra-programrriatic and 18% were inter-programmatic. The central research themes of the program include hematopoietic and noh-hematopoietic stem cell biology, hematopoietic cell transplant (HCT), immuriobiology and immune-based therapies as well as studies of tissue repair, peri-transplant complications, survivorship/late effects and quality of life. The Program emphasizes translational development of new agents for therapeutic application and testing in phase l-ll clinical trials with a future goal of moving Cancer Center investigator-initiated phase I and II studies to definitive, multi-institutional phase III clinical trials. The scientific goals of the program are to advance knowledge of human hematopoietic and non-hematopoietic stem cells and derivative populations, advance the understanding of innate and adaptive immunity and immune reconstitution and its use for therapy in conjunction with HCT, develop novel therapeutic approaches to eliminate or reduce the transplantassociated risks of graft failure, acute and chronic graft-versus-host disease (GVHD), opportunistic infection and relapse, and improve the short and long-term quality of life in HCT survivors. Since its inception in 1974, the TBT Program has been a world leader in the field, advancing and improving the effectiveness of transplant therapy through basic and translational research that is ultimately applied to the care of patients. TBT Program investigators use all resources of the University of Minnesota Cancer Center to advance both clinical and basic laboratory investigations.